As the incidence of neoplasms in rheumatic disease patients exposed to anti-TNFs is limited, characterization of neoplasms in this subset of patients is important to guide malignancy screening recommendations in anti-TNF treatment follow up care. Here, TNF is linked to rheumatic disorder.